Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy

Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer‐related mortality. Despite significant advances made in the treatment of other cancers, current chemotherapies offer little survival benefit in this disease. Pancreaticoduodenectomy offers patients the possibilit...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bryan W Miller, Jennifer P Morton, Mark Pinese, Grazia Saturno, Nigel B Jamieson, Ewan McGhee, Paul Timpson, Joshua Leach, Lynn McGarry, Emma Shanks, Peter Bailey, David Chang, Karin Oien, Saadia Karim, Amy Au, Colin Steele, Christopher Ross Carter, Colin McKay, Kurt Anderson, Thomas R Jeffry Evans, Richard Marais, Caroline Springer, Andrew Biankin, Janine T Erler, Owen J Sansom
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer Nature 2015-06-01
Col·lecció:	EMBO Molecular Medicine
Matèries:	animal models of cancer collagen cross‐linking lysyl oxidase pancreatic cancer
Accés en línia:	https://doi.org/10.15252/emmm.201404827
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!